Abstract: Objective: To investigate the effects of sacubitril valsartan sodium, dapagliflozin combined with finerenone on blood
glucose, blood pressure and renal function in type 2 diabetic nephropathy patients combined with hypertension. Methods: The clinical
data of 105 type 2 diabetic nephropathy patients combined with hypertension treated in the People′s Hospital of Xishuangbanna Dai
Autonomous Prefecture from February to December 2023 were retrospectively analyzed. Patients were divided into a control group and
an observation group according to different treatment regimens. The control group was treated with sacubitril valsartan sodium
combined with dapagliflozin, and the observation group was treated with finerenone on the basis of the control group. After 6 months of
continuous treatment, the blood glucose, blood pressure, renal function, plasma albumin and serum potassium levels of the two groups
were compared before and after treatment. Results: After 6 months of treatment, there were no obvious adverse reactions in two groups.
The blood pressure and blood glucose control in both groups improved significantly compared with that before treatment, and renal
function was significantly restored, and the blood pressure, renal function and plasma albumin control in the observation group were
better than those in the control group, and the differences were statistically significant （P<0.05）. Conclusion: Type 2 diabetic
nephropathy patients with hypertension were treated with finerenone on the basis of using sacubitril valsartan sodium and dapagliflozin,
which can effectively control the blood glucose and blood pressure of patients, delay the progress of nephrosis, and have positive
significance in protecting renal function.

Key words: sacubitril valsartan sodium, dapagliflozin, finerenone, diabetic nephropathy, renal function, serum potassium, blood
pressure